A Phase I/II Clinical Trial of LBL-033 in the Treatment of Advanced Malignant Tumors

Inclusion Criteria:

1. Agree to follow the experimental treatment plan and visit plan, join the groupvoluntarily, and sign a written informed consent form;

2. Age ≥ 18 years old when signing the informed consent form;

3. The Eastern Cooperative Oncology Group's physical status scoring standard (ECOG) is 0~1;

4. The expected survival time is at least 12 weeks;

5. According to the evaluation of RECIST 1.1 standard, the subjects enrolled have atleast one measurable Target lesion;

6. Subject has adequate organ and bone marrow function，Conforming to laboratory testresults:

7. Males with fertility and females of childbearing age are willing to take effectivecontraceptive measures From the signing of the informed consent form to within 6months after the last administration of the trial drug (including abstinence,intrauterine device, various hormonal contraception, correct use of contraceptionSets，etc）; Women of childbearing age include pre-menopausal women and women within 2years after menopause. Women of childbearing age must have a negative pregnancy testwithin 7 days before the first trial drug is administered.

Exclusion Criteria:

1. Have received other unmarketed clinical research drugs or treatments within 4 weeksbefore using the research drug for the first time;

2. Patients with active infection and currently requiring intravenous anti-infectivetreatment；

3. Those who have clinically uncontrollable pleural effusion, pericardial effusion ,requiring repeated drainage or medical intervention;

4. The patient has a Medical history of immunodeficiency, including HIV antibodypositive；

5. Women during pregnancy or lactation;

6. The investigator believes that the subject has other conditions that may affectcompliance or are not suitable for participating in this study.